Study on the preventive and therapeutic effect of Cordyceps militaris on patients with chronic obstructive pulmonary disease and insulin resistance based on gut microbiota
- Conditions
- chronic obstructive pulmonary disease
- Registration Number
- ITMCTR2000003781
- Lead Sponsor
- Shanghai Sixth People's Hospital East Campus
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Patients with chronic obstructive pulmonary disease (COPD), aged 45-75 years, of all genders, were enrolled in the insulin resistance COPD group according to the insulin resistance index (HOMA-IR) >= 2.29, and the healthy control group was also collected.
in line with the 2013 edition of global initiative for chronic obstructive pulmonary disease (gold): FEV1 / FVC accounted for less than 70% of the predicted value after using bronchodilators; chronic airway symptoms, including cough, dyspnea and chronic airway obstruction, were present; all patients were in clinical stable stage. The clinical stable period was defined as: no acute exacerbation symptoms, no use of hormone or antibiotics within 6 weeks before inclusion, and the dosage of inhaled drug dosage form remained unchanged; insulin resistance index (HOMA-IR) >= 2.29.
(1) At the same time, patients with suspected ACOS and confirmed ACOS were also accompanied by other clinical features related to asthma and pulmonary function, suggesting that FEV1 improvement rate was more than 12% and absolute value was higher than 200 ml.
(2) Pulmonary function indicated that there were restrictive ventilation dysfunction.
(3) Chest CT showed pneumonia, pulmonary abscess, active pulmonary tuberculosis, bronchiectasis, lung tumor, pulmonary interstitial disease, diffuse panbronchiolitis, pleural effusion, pneumothorax and other respiratory diseases.
(4) Combined with metabolic diseases: type 1 diabetes mellitus, hyperlipidemia, overweight or obesity (body mass index >= 24 kg/m2), etc.
(5) Combined with cardiovascular diseases: including heart failure, hypertension, atherosclerosis, etc.
(6) There are no known gastrointestinal diseases including irritable bowel syndrome, ulcerative colitis, and no history of bariatric surgery or drugs known to affect the immune system
(7) Other systemic diseases include cirrhosis, nonalcoholic cirrhosis and chronic kidney disease.
(8) Patients with cognitive impairment or mental disorder were unable to complete the COPD assessment test (CAT) questionnaire and the modified British Medical Research Council (MMRC) respiratory questionnaire.
(9) Metformin, acarbose, antibiotics, microbial preparations, lactulose, etc. within 6 weeks.
(10) Serious picky food, excessive drinking and overeating.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Abundance, species and function of gut microbiota;
- Secondary Outcome Measures
Name Time Method